Healthcare Industry News: Ash Access Technology
News Release - January 11, 2007
Ash Access Technology, Inc. Appoints Dr. Al Guillem as Vice President, Scientific and Quality AffairsSeasoned Executive Brings 25 Years of Pharmaceutical Development Experience
LAFAYETTE, IN--(Healthcare Sales & Marketing Network)--Jan 11, 2007 -- Ash Access Technology, Inc., a privately held specialty pharmaceutical and medical device company, announced today that Dr. Al Guillem will be joining the company as Vice President, Scientific and Quality Affairs. Dr. Guillem had been a consultant with the company since mid 2005, in the quality manufacturing of Zuragen(TM), the company's flagship antimicrobial / antithrombotic therapy. He will continue in that capacity as well as lead the development and execution of the company's formal quality system and FDA submissions.
For the past 25 years, Dr. Guillem has managed Quality, Regulatory Compliance, Product Development, Regulatory Affairs, Control and Development laboratories, and many other operational activities in several pharmaceutical companies. He has held senior positions in both large and start up pharmaceutical companies such as Wyeth, Boeringher Ingelheim, Medeva Americas and Adams Laboratories. Most recently, Al held the roles of Vice President of Quality and Pharmaceutical Science at Bone Care International and Vice President and General Manager at Adams Laboratories.
"I had already completed my due diligence on Ash Access and its promising products, at the time I became an investor," explained Dr. Guillem. "As I worked the last year and a half with the executives and development team in my role as a consultant, I was impressed with the quality, focus, and efficiency of the team. I believe we are in a great position to bring tremendous medical breakthroughs to the market, and I am pleased to be on such a high caliber team that's working well together to make it happen."
"We are very pleased to have Dr. Guillem formally join our executive team at Ash Access. His quality manufacturing expertise has been invaluable leading up to and during the clinical trial of Zuragen(TM)," commented Bob Truitt, President & CEO of Ash Access Technology, Inc. "Al fills a vital role as we continue to build a world-class team that will bring high quality vascular access products to commercialization."
Zuragen(TM) is a non-antibiotic, injectable therapy designed to significantly reduce the incidence of catheter-related bloodstream infections (CRBSI) as well as maintain catheter patency. In pre-clinical lab studies, Zuragen(TM) demonstrated significant efficacy against a broad spectrum of common bacteria associated with CRBSI and complete elimination of biofilm. A large-scale clinical trial, made possible in a large part by a generous two million dollar grant from the Indiana 21st Century Research and Technology Fund (see release for details) and a $2.7M SBIR Fast-Track Grant from the NIH NIDDK, is currently underway evaluating the efficacy and safety of Zuragen(TM) in hemodialysis patients.
Ash Access Technology, Inc. (www.ashaccess.com) is a privately held company founded to develop antimicrobial and vascular access technologies, devices and methodologies to combat the deadly and expensive problem of catheter-related bloodstream infections, with an emphasis on prevention. Dr. Stephen R. Ash, Chairman and Director, Research and Development, is a practicing Nephrologist with the Arnett Clinic in Lafayette, Indiana, and is a world-recognized researcher and patent holder in extracorporeal devices, sorbent chemistry, and vascular and peritoneal access devices. Ash Access Technology is located in Lafayette, Indiana in the INOK Business Center.
This press release contains forward-looking statements, which if not based on historical facts, involve risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company's control.
Source: Ash Access Technology
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.